Benitec Biopharma Inc. Research and Development Expense
Benitec Biopharma Inc. (BNTC) reported Research and Development Expense of $23.39 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-09-14
- Benitec Biopharma Inc. research and development expense for the quarter ending 2026-06-30 was $7.89M, a 175.06% increase year-over-year.
- Benitec Biopharma Inc. research and development expense for the quarter ending 2026-03-31 was $6.30M, a 3.03% decline year-over-year.
- Benitec Biopharma Inc. research and development expense for the quarter ending 2025-12-31 was $5.83M, a 8.34% increase year-over-year.
- Benitec Biopharma Inc. research and development expense for the quarter ending 2025-09-30 was $3.37M, a 6.00% decline year-over-year.
- Benitec Biopharma Inc. research and development expense for fiscal 2026 was $23.39M, a 27.58% increase from fiscal 2025.
- Benitec Biopharma Inc. research and development expense for fiscal 2025 was $18.33M, a 17.45% increase from fiscal 2024.
- Benitec Biopharma Inc. research and development expense for fiscal 2024 was $15.61M, a 22.19% increase from fiscal 2023.
- Benitec Biopharma Inc. research and development expense for fiscal 2023 was $12.77M, a 13.33% increase from fiscal 2022.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-14 | $14.18M derived: sum of 2 quarters · filed 2026-09-14 | $20.02M derived: sum of 3 quarters · filed 2026-09-14 | $23.39M 10-K · filed 2026-09-14 | |||
| 2026-03-31 | $6.30M 10-Q · filed 2026-05-14 | $12.13M derived: sum of 2 quarters · filed 2026-05-14 | $15.50M 10-Q · filed 2026-05-14 | $18.37M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2025-12-31 | $5.83M 10-Q · filed 2026-02-12 | $9.20M 10-Q · filed 2026-02-12 | $12.07M derived: sum of 3 quarters · filed 2026-03-20 | $18.57M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2025-09-30 | $3.37M 10-Q · filed 2025-11-14 | $6.24M derived: sum of 2 quarters · filed 2026-03-20 | $12.73M derived: sum of 3 quarters · filed 2026-05-14 | $18.12M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2025-06-30 | $2.87M 10-K/A · filed 2026-03-20 | $9.36M derived: sum of 2 quarters · filed 2026-05-14 | $14.75M derived: sum of 3 quarters · filed 2026-05-14 | $18.33M 10-K · filed 2026-09-14 | |||
| 2025-03-31 | $6.50M 10-Q · filed 2026-05-14 | $5.98M 10-Q · filed 2025-05-14 | $11.88M derived: sum of 2 quarters · filed 2026-05-14 | $15.46M 10-Q · filed 2026-05-14 | $14.64M 10-Q · filed 2025-05-14 | $18.98M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $5.38M 10-Q · filed 2026-02-12 | $5.07M 10-Q · filed 2025-02-14 | $8.97M 10-Q · filed 2026-02-12 | $8.66M 10-Q · filed 2025-02-14 | $12.48M derived: sum of 3 quarters · filed 2026-03-20 | $15.05M derived: sum of 4 quarters · filed 2026-03-20 | |
| 2024-09-30 | $3.58M 10-K/A · filed 2026-03-20 | $7.10M derived: sum of 2 quarters · filed 2026-03-20 | $9.66M derived: sum of 3 quarters · filed 2026-03-20 | $14.77M derived: sum of 4 quarters · filed 2026-03-20 | |||
| 2024-06-30 | $3.51M derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-20 | $6.08M derived: sum of 2 quarters · filed 2026-03-20 | $11.18M derived: sum of 3 quarters · filed 2026-03-20 | $15.61M 10-K/A · filed 2026-03-20 | |||
| 2024-03-31 | $2.57M 10-Q · filed 2025-05-14 | $7.67M derived: sum of 2 quarters · filed 2025-05-14 | $12.10M 10-Q · filed 2025-05-14 | $15.28M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $5.10M 10-Q · filed 2025-02-14 | $9.53M 10-Q · filed 2025-02-14 | $12.72M derived: sum of 3 quarters · filed 2025-02-14 | $15.88M derived: sum of 4 quarters · filed 2025-02-14 | |||
| 2023-09-30 | $4.43M 10-Q · filed 2024-11-14 | $7.62M derived: sum of 2 quarters · filed 2024-11-14 | $10.78M derived: sum of 3 quarters · filed 2024-11-14 | $14.54M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $6.35M derived: sum of 2 quarters · filed 2024-09-26 | $10.11M derived: sum of 3 quarters · filed 2024-09-26 | $12.77M 10-K · filed 2024-09-26 | |||
| 2023-03-31 | $3.17M 10-Q · filed 2024-05-13 | $6.93M derived: sum of 2 quarters · filed 2024-05-13 | $9.59M 10-Q · filed 2024-05-13 | $12.76M derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | $3.76M 10-Q · filed 2024-02-13 | $6.42M 10-Q · filed 2024-02-13 | $9.60M derived: sum of 3 quarters · filed 2024-02-13 | $11.77M derived: sum of 4 quarters · filed 2024-02-13 | |||
| 2022-09-30 | $2.66M 10-Q · filed 2023-11-13 | $5.84M derived: sum of 2 quarters · filed 2023-11-13 | $8.01M derived: sum of 3 quarters · filed 2023-11-13 | $11.15M derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $3.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-21 | $5.35M derived: sum of 2 quarters · filed 2023-09-21 | $8.49M derived: sum of 3 quarters · filed 2023-09-21 | $11.27M 10-K · filed 2023-09-21 | |||
| 2022-03-31 | $2.17M 10-Q · filed 2023-05-15 | $5.32M derived: sum of 2 quarters · filed 2023-05-15 | $8.10M 10-Q · filed 2023-05-15 | $10.42M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $3.15M 10-Q · filed 2023-02-13 | $5.93M 10-Q · filed 2023-02-13 | $8.25M derived: sum of 3 quarters · filed 2023-02-13 | $11.00M derived: sum of 4 quarters · filed 2023-02-13 | |||
| 2021-09-30 | $2.78M 10-Q · filed 2022-11-10 | $5.10M derived: sum of 2 quarters · filed 2022-11-10 | $7.86M derived: sum of 3 quarters · filed 2022-11-10 | $9.03M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | $2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-02 | $5.08M derived: sum of 2 quarters · filed 2022-09-02 | $6.25M derived: sum of 3 quarters · filed 2022-09-02 | $7.02M 10-K · filed 2022-09-02 | |||
| 2021-03-31 | $2.76M 10-Q · filed 2022-05-16 | $3.93M derived: sum of 2 quarters · filed 2022-05-16 | $4.70M 10-Q · filed 2022-05-16 | $5.61M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $1.17M 10-Q · filed 2022-02-14 | $1.94M 10-Q · filed 2022-02-14 | $2.85M derived: sum of 3 quarters · filed 2022-02-14 | $3.65M derived: sum of 4 quarters · filed 2022-02-14 | |||
| 2020-09-30 | $774.00K 10-Q · filed 2021-11-15 | $1.68M derived: sum of 2 quarters · filed 2021-11-15 | $2.48M derived: sum of 3 quarters · filed 2021-11-15 | $3.08M derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | $906.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-20 | $1.71M derived: sum of 2 quarters · filed 2021-09-20 | $2.31M derived: sum of 3 quarters · filed 2021-09-20 | $3.00M 10-K · filed 2021-09-20 | |||
| 2020-03-31 | $805.00K 10-Q · filed 2021-05-12 | $1.40M derived: sum of 2 quarters · filed 2021-05-12 | $2.10M 10-Q · filed 2021-05-12 | ||||
| 2019-12-31 | $599.00K 10-Q · filed 2021-02-09 | $1.02M 10-Q · filed 2021-02-09 | |||||
| 2019-09-30 | $423.00K 10-Q · filed 2020-11-13 | ||||||
| 2019-06-30 | $4.57M 10-K · filed 2020-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |